tWAN Biotech Co., Ltd. 圖遠生物科技股份有限公司
tWAN Biotech provides cloud-native imaging services for clinical trials, focusing on streamlining workflows for surrogate imaging endpoints and quantitative imaging biomarkers. They cater to novel drugs, medical devices, and imaging AI. Their services include imaging trial design, development of imaging charter and documents, data management, and image re-read/rescue studies. They specialize in efficacy endpoints (PFS, MRI-PDFF), safety endpoints (ARIA-E, ARIA-H, Cardiotoxicity), patient selection (CT Perfusion), and Central Reading (BICR) management. Their cloud-based platform ensures secure data transmission, structured reviews, audit trails, and seamless data integration, adhering to data privacy regulations. They serve therapeutic areas like Oncology, Cardiovascular, CNS, Gastroenterology, and Rheumatology, utilizing imaging modalities such as CT, MRI, PET, Ultrasound, and Hybrid Scanners. tWAN Biotech is the leading Central Reading and BICR service provider in Taiwan.
tWAN Biotech Co., Ltd. 圖遠生物科技股份有限公司
tWAN Biotech provides cloud-native imaging services for clinical trials, focusing on streamlining workflows for surrogate imaging endpoints and quantitative imaging biomarkers. They cater to novel drugs, medical devices, and imaging AI. Their services include imaging trial design, development of imaging charter and documents, data management, and image re-read/rescue studies. They specialize in efficacy endpoints (PFS, MRI-PDFF), safety endpoints (ARIA-E, ARIA-H, Cardiotoxicity), patient selection (CT Perfusion), and Central Reading (BICR) management. Their cloud-based platform ensures secure data transmission, structured reviews, audit trails, and seamless data integration, adhering to data privacy regulations. They serve therapeutic areas like Oncology, Cardiovascular, CNS, Gastroenterology, and Rheumatology, utilizing imaging modalities such as CT, MRI, PET, Ultrasound, and Hybrid Scanners. tWAN Biotech is the leading Central Reading and BICR service provider in Taiwan.